Latest press releases May 16 2024 MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa May 07 2024 MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Apr 10 2024 MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions View All News View All Press Releases + Upcoming events Jun 5 - Jun 6 2024 Jefferies 2024 Global Healthcare Conference Jun 10 - Jun 13 2024 Goldman Sachs 45th Annual Global Healthcare Conference Jun 12 - Jun 15 2024 EULAR View All Events View All Events + Corporate presentations MoonLake R&D Day 10th March View All Presentations View All Presentations + IR contact details Carla Bretes Director Investor Relations and Business Development e: ir@moonlaketx.com
May 16 2024 MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
May 07 2024 MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
Apr 10 2024 MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions